相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody for the Prevention of Staphylococcal Bloodstream Infections, in Very-Low-Birth-Weight Neonates
Leonard E. Weisman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus
Daniel J. Wallace et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma
Akihiro Takeshita et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Ipilimumab: controversies in its development, utility and autoimmune adverse events
Jeffrey Weber
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years
Kevan C. Herold et al.
CLINICAL IMMUNOLOGY (2009)
Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
J. Veeken et al.
CURRENT CANCER DRUG TARGETS (2009)
Anti-CD3 mAbs for treatment of type 1 diabetes
Adam Kaufman et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2009)
Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations
Florence Roufosse
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Insulin-like growth factor receptor type I as a target for cancer therapy
Liliane Goetsch et al.
IMMUNOTHERAPY (2009)
Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults
Leonard E. Weisman et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2009)
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus
Michael P. Cancro et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Gastrosplenic Fistula From Hodgkin's Lymphoma
Carolyn D. Seib et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I Dose Escalation, Pharmacokinetic and Pharmacodynamic Study of Naptumomab Estafenatox Alone in Patients With Advanced Cancer and With Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer
Hossein Borghaei et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
被撤回的出版物: Phase II Study of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small-Cell Lung Cancer (Retracted article. See vol. 30, pg. 4179, 2012)
Daniel D. Karp et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
P164 - Clinical pharmacology of vedolizumab (MLN0002) in patients with active ulcerative colitis
C. Scholz et al.
Journal of Crohns & Colitis (2009)
Tanezumab, an Anti-Nerve Growth Factor (NGF) antibody, for the treatment of chronic low back pain (CLBP) – a randomized, controlled, double-blind, phase 2 trial
N. Katz et al.
JOURNAL OF PAIN (2009)
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-alpha(4)beta(7) Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
Dulce Soler et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
New challenges to medicare beneficiary access to mAbs
Joshua Cohen et al.
MABS (2009)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross et al.
ONCOLOGIST (2009)
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis
Alexa B. Kimball et al.
ARCHIVES OF DERMATOLOGY (2008)
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis - A phase I/II randomized, blinded, placebo-controlled, dose-ranging study
Mark C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2008)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer
Chia C. Portera et al.
CLINICAL CANCER RESEARCH (2008)
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Brian G. Feagan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Monoclonal Antibodies as Innovative Therapeutics
Janice M. Reichert
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2008)
DCE-MRI endpoints reveal decreased tumor vascularity in patients with liver metastases: a Phase I dose escalating study with IMC-1121B
N. J. Serkova et al.
EJC SUPPLEMENTS (2008)
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A pilot study:: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost
David A. Reardon et al.
NEURO-ONCOLOGY (2008)
Treatment of patients with the hypereosinophilic syndrome with mepolizumab
Marc E. Rothenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
被撤回的出版物: The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility (Retracted article. See vol. 109, pg. 5548, 2012)
Jeroen J. Larnmerts van Bueren et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The use of galiximab in non-hodgkin lymphoma
Sanjay Vinjamaram et al.
CLINICAL LYMPHOMA & MYELOMA (2008)
Interleukin-12, interleukin-23, and psoriasis: Current prospects
Dorothea C. Torti et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
Stephanie G. Downey et al.
CLINICAL CANCER RESEARCH (2007)
A phase lb study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours
G. Attard et al.
BRITISH JOURNAL OF CANCER (2007)
Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck
Lars Bastholt et al.
RADIOTHERAPY AND ONCOLOGY (2007)
Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia
John C. Byrd et al.
CLINICAL CANCER RESEARCH (2007)
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma
J. P. Leonard et al.
ANNALS OF ONCOLOGY (2007)
Mechanisms of antibody immunotherapy on clonal islet reactive T cells
P. van de Linde et al.
HUMAN IMMUNOLOGY (2006)
A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma
I Bleumer et al.
JOURNAL OF UROLOGY (2006)
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
Thomas Doerner et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Phase I/II study of galiximab, an Anti-CD80 antibody, for relapsed or refractory follicular lymphoma
MS Czuczman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
B Keymeulen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin
BG Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes
KC Herold et al.
DIABETES (2005)
Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophihc syndrome
AD Klion et al.
BLOOD (2004)
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
I Bleumer et al.
BRITISH JOURNAL OF CANCER (2004)
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
JF DiJoseph et al.
BLOOD (2004)
Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700
YJ Kim et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
FS Hodi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
KC Herold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
RB DeMattos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
分享论文
